These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2616932)

  • 1. The performance of the two-stage analysis of two-treatment, two-period crossover trials.
    Freeman PR
    Stat Med; 1989 Dec; 8(12):1421-32. PubMed ID: 2616932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The performance of a two-stage analysis of ABAB/BABA crossover trials.
    Kabaila P; Vicendese M
    Biom J; 2012 May; 54(3):361-9. PubMed ID: 22685002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using the maximum test statistic in the two-period crossover clinical trial.
    Willan AR
    Biometrics; 1988 Mar; 44(1):211-8. PubMed ID: 3358989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carryover and the two-period crossover clinical trial.
    Willan AR; Pater JL
    Biometrics; 1986 Sep; 42(3):593-9. PubMed ID: 3567292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple method for the estimation of interaction bias in crossover studies.
    Cleophas TJ
    J Clin Pharmacol; 1990 Nov; 30(11):1036-40. PubMed ID: 2243151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the crossover design in the presence of residual effects.
    Lehmacher W
    Stat Med; 1991 Jun; 10(6):891-9. PubMed ID: 1876779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The crossover experiment for clinical trials.
    Brown BW
    Biometrics; 1980 Mar; 36(1):69-79. PubMed ID: 7370374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian analysis of the two-period crossover design for clinical trials.
    Grieve AP
    Biometrics; 1985 Dec; 41(4):979-90. PubMed ID: 3830262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of two-period crossover design in a multicenter clinical trial.
    Castellana JV; Patel HI
    Biometrics; 1985 Dec; 41(4):969-77. PubMed ID: 3830261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crossover trials comparing several treatments.
    Newcombe RG
    J Clin Periodontol; 1992 Nov; 19(10):785-7. PubMed ID: 1452805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critique of recent research on the two-treatment crossover design.
    Fleiss JL
    Control Clin Trials; 1989 Sep; 10(3):237-43. PubMed ID: 2676339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crossover trials with a binary response: a powerful method despite the carryover effect.
    Cleophas TJ; van Lier HJ
    J Clin Pharmacol; 1996 Mar; 36(3):198-202. PubMed ID: 8690812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of two methods of estimating a common risk difference in a stratified analysis of a multicenter clinical trial.
    O'Gorman TW; Woolson RF; Jones MP
    Control Clin Trials; 1994 Apr; 15(2):135-53. PubMed ID: 8205804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple testing in clinical trials.
    Bauer P
    Stat Med; 1991 Jun; 10(6):871-89; discussion 889-90. PubMed ID: 1831562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of treatment allocation procedures on nominal significance levels and bias.
    Kalish LA; Begg CB
    Control Clin Trials; 1987 Jun; 8(2):121-35. PubMed ID: 3608506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-stage trial design for testing treatment, self-selection and treatment preference effects.
    Rücker G
    Stat Med; 1989 Apr; 8(4):477-85. PubMed ID: 2727471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On design considerations and randomization-based inference for community intervention trials.
    Gail MH; Mark SD; Carroll RJ; Green SB; Pee D
    Stat Med; 1996 Jun; 15(11):1069-92. PubMed ID: 8804140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A note on misspecification in general linear models with correlated errors for the analysis of crossover clinical trials.
    Wang W; Cong N; Chen T; Zhang H; Zhang B
    PLoS One; 2019; 14(3):e0213436. PubMed ID: 30870443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carryover negligibility and relevance in bioequivalence studies.
    Ocaña J; Sanchez O MP; Carrasco JL
    Pharm Stat; 2015; 14(5):400-8. PubMed ID: 26175204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-period crossover designs for two treatments.
    Ebbutt AF
    Biometrics; 1984 Mar; 40(1):219-24. PubMed ID: 6733230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.